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Abstract
Background
In adult patients with Duchenne muscular dystrophy (DMD) life-threatening constipation
has been reported. Since gastrointestinal function in DMD has not been rigorously studied
we investigated objective and subjective manifestations of gastrointestinal disturbances in
DMD patients.
Methods
In 33 patients with DMD, age 12–41 years, eating behavior and gastrointestinal symptoms
were evaluated by questionnaires. Gastric emptying half time (T1/2) and oro-cecal transit
time (OCTT) were evaluated by analyzing 13CO2 exhalation curves after ingestion of 13C
labeled test meals. Colonic transit time (CTT) was measured by abdominal radiography fol-
lowing ingestion of radiopaque markers.
Results
The median (quartiles) T1/2 was 187 (168, 220) minutes, the OCTT was 6.3 (5.0, 7.9)
hours, both substantially longer than normal data (Goetze 2005, T1/2: 107±10; Geypens
1999, OCTT 4.3±0.1 hours). The median CTT was 60 (48, 82) hours despite extensive use
of laxative measures (Meier 1995, upper limit of normal: 60 hours). T1/2 and OCTT did not
correlate with symptoms evaluated by the Gastroparesis Cardinal Symptom Index (GCSI)
(Spearman r = -0.3, p = 0.1; and r = -0.15, p = 0.4, respectively). CTT was not correlated
with symptoms of constipation assessed by ROME III criteria (r = 0.12, p = 0.5).
Conclusions
DMD patients have a markedly disturbed gastrointestinal motor function. Since objective
measures of impaired gastrointestinal transport are not correlated with symptoms of
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gastroparesis or constipation our findings suggest that measures assuring adequate intesti-
nal transport should be taken independent of the patient’s perception in order to prevent
potentially life threatening constipation, particularly in older DMD patients.
Introduction
DuchenneMuscular Dystrophy (DMD) is the most common form of the inheritedmuscular
dystrophies affecting approximately one in 3,300 male births. The disorder is caused by muta-
tions in the gene located at Xp21, which codes for the dystrophin protein. DMD leads to pro-
gressive muscular weakness, severe physical disability and ultimately death.[1, 2] Most DMD
patients becomewheelchair-bound in childhood, and they depend largely on their parents or
caregivers for their daily activities and care.[3, 4] In more advanced stages of the disease, the
progressive spinal and chest wall deformity and the impairment of respiratory muscle function
lead to hypercapnic respiratory failure around the age of 20 years, and cardiac muscle involve-
ment may entail congestive heart failure.[5] Non-invasive positive-pressure ventilation and
other supportive measures prolong survival of patients with DMD,[6] who report a surpris-
ingly high quality of life in domains not directly related to their physical impairment.[6]
With advancing age, DMD patients may suffer from nutritional problems due to swallowing
impairment, collection of gastric air, gastro-esophageal reflux and chronic constipation that
may lead to life threatening complications.[7] However, this has not been systematically evalu-
ated in scientific studies, and there is little scientific information on the possible mechanisms
and treatment of these conditions in DMD patients.[8–12] In mice models, though, alterations
of the myenteric plexus associated with reducedmyoelectrical slow wave activity[13, 14] along
with a reduced availability of NO[15, 16] due to lack of dystrophin acting as an anchor for NO-
synthase have been implicated in impaired GITmotility.
The purpose of this study is to evaluate the type and prevalence of subjective and objective
gastrointestinal disturbances in DMD patients. We hypothesized that the gastrointestinal
transport in DMD patients was delayed in comparison to reference values reported for healthy
subjects.
Methods
Patients
Male patients with DMD attending the outpatient clinic of the PulmonaryDivision and Neuro-
muscular Center at the University Hospital of Zurich were asked to participate. Inclusion crite-
ria were: diagnosis of DMD based on genetic and/or typical clinical findings including
muscular biopsy, age greater than 7 years, and a stable condition during the last 3 months.
Exclusion criteria were: acute infection or respiratory failure, acute gastro-intestinal motility
problems such as Ogilvie Syndrome, and surgery in the last 3 months. We included 33 patients
of which 26 were living in a long-term care facility, the Mathilde Escher Heim, while 7 patients
were living with their family in private homes. The patients receive state-of-the-art long-term
care[17, 18] comprising regular follow-up examinations and treatment for musculoskeletal,
respiratory, cardiac, gastrointestinal and other problems as appropriate. Patients had to be in
stable conditions during the last three months.
Informed consent was obtained from all participants. If a participant was physically unable
to document his consent in writing, a caregiver and the director of nursing services
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documented the oral informed consent. Participants below the legal age of 18 years were addi-
tionally required to have at least on parent to co-sign the informed consent. The study was
approved by the institutional ethics committee (Kantonale Ethikkommission Zürich;
KEK-ZH-Nr. 2010–0289).
Clinical and questionnaire evaluation
Assessment comprisedmedical history, questionnaires on physical impairment, food and fluid
intake, gastro-intestinal function, and a physical examination. Physical impairment and depen-
dency on care was evaluated by the Duchennemuscular dystrophy Impairment and Depen-
dency on care score (DID score)[6] that evaluates eight domains of daily living, each rated on a
scale from 1 (in one domain 2) to 10 points with increasing dependency. A total DID score of 9
represents no impairment at all; a score of 80 represents complete impairment and dependency
on care. The score is calculated based on the functional status in eight different aspects (mobil-
ity with and without technical aids, transfer, static body control, changes of body position, get-
ting dressed, eating and drinking and breathing). We assessed age as a continuous and binary
variable and defined “older patients” as being over 21 years old.
Patients reported their type and amount of food and fluid intake, and enteral feeding via
percutaneous enterostomy tube, and the quantity and quality of bowel movements[19] over a
period of three consecutive weeks.
Dyspepsia was assessed by the Short-Form LeedsDyspepsiaQuestionnaire (SF-LDQ) that
evaluates indigestion, heartburn, regurgitation and nausea on a scale from 0 to 4 with increas-
ing frequency and interference with daily life and a question about the most prevalent symp-
tom is also included. A score of 7 of 32 points is considered as indicative for dyspepsia.[20]
Delayed gastric emptying (GE) was evaluated by the Gastroparesis Cardinal Symptom Index
(GCSI) evaluating nine symptoms (stomach fullness, loss of appetite, inability to finish a meal,
excessive postprandial fullness, bloating, subjectively enlarged stomach, nausea, retching and
vomiting) each graded from 0 to 5. Gastroparesis is considered to be present with a score of
>18 of 32 points.[21] Lower gastrointestinal symptoms and constipation were assessed by the
Rome III Criteria for functional constipation including answers to 17 questions about abdomi-
nal discomfort, pain, frequency and quality of bowel movements, stool quality and duration of
symptoms. Presence or absence of functional constipation was then decided based on the
Rome III criteria for constipation (straining during defecation, lumpy or hard stools, sensation
of incomplete defecation, sensation of obstruction, use of manual maneuvers to facilitate defe-
cation, fewer than three defecations per week, no loose stools without use of laxatives, and the
absence for criteria of irritable bowel syndrome).[22]
Gastric and intestinal transit measurements
Gastric and intestinal transits were evaluated by established tests based on monitoring 13CO2
concentration in exhaled air after ingestion of labeled food. Colonic transit was evaluated by
abdominal radiography performed after ingestion of radiopaque markers.
Thus, gastric emptying and oro-cecal transit were assessed by measuring the change in
13CO2 concentration in the exhaled air after ingestion of a standardized test meal labeled with
the (non-radioactive) 13C isotope. All participants remained fasted and were asked to refrain
from smoking over night prior to the assessment of gastric emptying and oro-cecal transit. For
assessment of gastric emptying a test meal consisting of 60 g of scrambled pasteurized egg
mixed with 100 mg 13C-sodium-octanoate (Euriso-Top, Saint-Aubin Cedex, France) on 60 g of
white bread and 1 g of butter was administered (240 kcal, 1005 kJ).[23, 24] Intestinal transport
was evaluated by measuring the oro-cecal transit time (OCTT)using lactose 13C–ureide
Gastrointestinal Dysfunction in DMD
PLOS ONE | DOI:10.1371/journal.pone.0163779 October 13, 2016 3 / 14
(Euriso-Top, Saint-Aubin Cedex, France) as a tracer after a standardized priming of the colonic
flora with 1 g of unmarked lactose ureide per day over the course of 5 days.[25–27] The test
meal was identical to the one served for gastric emptying, but instead of having 13C-sodium-
octanoate added to the egg, 100mg of lactose 13C–ureide was blended into the butter.
After ingestion of test meals, exhaled air was sampled every 15 minutes for 8 hours for gas-
tric emptying as well as OCTT and subsequently every 30 minutes up to 12 hours for OCTT
only. The time interval between tests was a mean (interquartile range) of 33 (10, 52) days, with
a minimum of 1 day in two subjects. In spontaneously breathing patients, exhaled air was sam-
pled by letting them exhale into a plastic bag after a full inspiration. In patients on assisted ven-
tilation, exhaled air was sampled through a side port at the tracheostoma. Sample analysis was
done by non-dispersive isotope selective infrared spectroscopy (NDIRS, IRIS,Wagner Analy-
sen Technik, Germany).[28, 29] Gastric emptying coefficient (GEC), the gastric emptying lag
time (Tlag; time to maximal 13CO2 excretion), and half time (T1/2; the time it takes 50% of the
13C dose to be excreted) were calculated by use of a non linear regression model of 13C recovery
in exhaled air according to Ghoos et al.[23]. Fig 1, visualizes the concept of gastric empting lag
time and half time. OCTTwas determined by recording a greater than 2‰ change of 13C
enrichment over baseline in exhaled air (delta over baseline, DOB> 2‰) as described by
Wutzke et al.[30] Results of measures of gastrointestinal transit were compared to the following
values observed in normal controls (mean±SD): gastric emptying lag time 70.1±10.2 minutes,
[31] gastric emptying half time 107.3±9.9 minutes,[31] gastric emptying coefficient 3±0.4[31]
and oro-cecal transit time 3.0±1.4 hours.[25] A deviation by>1SD from the mean was defined
as abnormal.
Fig 1. Illustration of the analysis and typically reported time points in gastric emptying. Lag Time
(Tlag; time to maximal 13CO2 excretion), and half time (T1/2; the time it takes 50% of the 13C dose to be
excreted) DOB: Delta Over Baseline (percentage of 13CO2 recovered). cPDR: cumulative Percentage Dose
Recovered.
doi:10.1371/journal.pone.0163779.g001
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Colonic transit time (CTT) was measured after ingestion of a capsule (P. & A. Mauch,
Münchenstein, Switzerland) each containing 10 radiopaque markers, daily for six consecutive
days. On the seventh day, an abdominal radiograph was taken. CTTwas computed in hours as
the sum of retainedmarkers multiplied by 2.4 (accounting for the administration of 10 markers
per 24 h).[32] A CTT greater than 60 h in men independent of smoking status, 66 hours for
smokers and 44 hours for never-smokers (90th percentile) is considered as delayed.[33]
Statistical analysis
Data are summarized as medians (interquartile range) and means (SD) for not normally and
normally distributed data, respectively. Correlations were calculated using Spearman's rank
correlation test. Multiple logistic regression was used to evaluate the association of age, extent
of physical impairment, positive pressure ventilation and medication with gastrointestinal
transit. Statistical analysis was programmed in SAS 9.3 (SAS Institute Inc., Cary, NC, USA). A
probability of p<0.05 was considered as significant.
Results
Patient characteristics and questionnaire evaluation
Thirty-three patients with a mean age of 24 (range 12–41) years were examined.Most were
severely physically impaired and dependent on a wheelchair as reflected in a mean Duchenne
impairment score of 56.7. Twenty-three participants (70%) required mechanical ventilation; of
these nine (27% of all patients) had assisted ventilation during 24 hours a day. Twenty-one par-
ticipants (64%) regularly used laxative or prokinetic medication.
The Rome III ConstipationModule was positive for constipation in 23 participants (70%).
The SF-LDQ score revealed a mean of 3.73 (range 0 to 10; 7 participants having a score7
indicating dyspepsia).[20] The median GCSI score was 9 (range 0 to 25, with 5 participants
having a score>18 suggesting definitive gastroparesis). Major complaints assessed by the
GCSI were inability to finish a normal-sizedmeal, postprandial fullness and bloating (with a
median item score of 1.9, 1.7 and 1.7, respectively; Table 1).[21, 34] Underlying data to all
reported results can be found in S1 Table.
Table 1. Patient characteristics and questionnaire evaluation.
n Percent Median Lower Quartile Upper Quartile
Age at time of exam 33 23.00 19.00 27.00
Duchenne impairment score 33 62 57 71
Medication
• Laxative medication 21/33 64%
• ACE inhibitor medication 11/33 33%
• Clyster or enemas 6/33 28%
• Any prokinetic or laxative medication 21/33 64%
Short Form-Leeds Dyspepsia Questionnaires sum 33 3.00 1.00 5.00
Gastroparesis Cardinal Symptom Index, sum 33 9.00 6.00 15.00
Rome III Criteria score, % of participants positive for constipation 23 70%
Forced Expiratory Volume 1sec, % predicted 25 18.0 11.0 30.0
Forced Vital Capacity, % predicted 25 16.0 10.0 30.0
Positive pressure ventilation 23/33 70%
24 hour/day positive pressure ventilation 9/33 27%
Percutaneous endoscopic gastrostomy (PEG) tube 9/33 27%
doi:10.1371/journal.pone.0163779.t001
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Measures of gastrointestinal transit
Objectivemeasures. One patient could not be assessed with the 13C method because of an
intercurrent infection requiring antibiotics. Three patients were not able to have their CTT
assessed because of the inability to swallow the radiopaque markers.
Gastric emptying was delayed as quantified by medians (interquartile ranges) of the gastric
emptying measures lag time (Tlag) and half time (T1/2) of 134 (109, 164) and 187 (186, 220)
minutes, respectively. Thus, all participants had prolonged values above the upper limit of nor-
mal (ULN; 80 minutes and 117 minutes respectively) as defined above based on previously
published healthy individuals.[31] There was no statistically significant difference between par-
ticipants who didn’t have any positive pressure ventilation (PPV; n = 10) with a T T1/2 of 201
(182, 230) minutes, and participants who needed PPV (n = 23) with a T1/2 of 183(131, 211)
minutes (p = 0.2; Fig 2). Correspondingly, the gastric emptying coefficientswere low, median
2.9 (2.4, 2.9), compared to the lower limit of normal (LLN: 2.6)[31] (Table 2).
The oro-cecal transit time (OCTT)was prolonged, i.e., 6.3 (5.0, 7.9) hours, compared to pre-
viously published data (ULN: 4.4 hours). [25] There was no statistically significant difference
between participants who didn’t have any PPV with an OCTTof 6.2 (5.5, 7.8) hours, and par-
ticipants who needed PPV with an OCTTof 6.3 (4.9, 8.0) hours (p = 0.5; Fig 3).
Fig 2. Exhaled breath analysis for assessment of gastric emptying in 32 patients. The median (IQR) changes over baseline of 13C enrichment
(Delta over baseline, DOB) in exhaled air after ingestion of the test meal are shown along with the cumulative percentage dose recovered (cPDR).
The vertical dashed lines (patients on PPV: long dashed vertical line at 183 minutes; spontaneously breathing patients: short dashed vertical line at
201 minutes) indicate the median time to recovery of 50% cumulative dose. It was considerably longer than the half time of normal controls (solid
vertical line at 107 minutes).[31]
doi:10.1371/journal.pone.0163779.g002
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The colonic transit time (CTT) was also rather long, median (interquartile range) of 60
(49, 82) hours, despite the use of laxative and prokinetic measures in 21 out of 32 patients. Six-
teen out of all 30 patients assessed for CTT (54%) and 21 out of 27 (78%) non-smoking
patients had an elevated CTT above the 90th percentile. Fourteen of the 30 participants (47%)
had an rectal accumulation of the radiopaque markers indicating a pelvic outlet obstruction,
while the remainder had a more diffuse pattern of marker distribution indicating slow transit
constipation. A representative example of an abdominal radiograph with markers is shown in
Fig 4.
Clinical characteristicsand gastrointestinal transit. To evaluate associations among clin-
ical characteristics and measures of gastrointestinal transit with increasing age and more pro-
nounced physical impairment, exploratory Spearman correlation analyses were performed.
These revealed significant associations of higher DID scores with the Rome III criteria for con-
stipation score as well as with the gastroparesis cardinal symptom index (GCSI). More
impaired patients were also significantlymore likely to use prokinetic or laxative medication.
Similar results were found for older patients (Table 3).
Although Tlag as well as T1/2 were similar in patients older than 21 years of age compared to
younger patients (Table 3) they were significantly shorter in older patients when age was used
as a continuous variable (coefficient -0.38, p = 0.03 and coefficient -0.37, p = 0.04, respectively).
To further evaluate this finding and control for confounding factors, multiple regression was
performed. This confirmed the significant inverse relationship between older age and Tlag and
T1/2 when adjusted for use of laxative and prokinetic medication as well as positive pressure
ventilation (coefficient -35.4, p = 0.02 and coefficient -56.5, p = 0.01, respectively). Adjustment
for positive pressure ventilation and prokinetic and laxative medication use also confirmed the
significant association between the DID score and the GCSI (coefficient 0.21, p = 0.048). The
same analysis restricted to ventilated patients only showed an even stronger association (coeffi-
cient 0.54, p = 0.0002).
Symptoms and objectivemeasures of gastrointestinal transit. We further evaluated
whether subjective symptoms were correlated with objectivemeasures of gastrointestinal
transport.We found that gastric emptying and oro-cecal transit time were neither signifi-
cantly associated with symptoms measured by the subjective GCSI, nor the SF-LDQ
(Table 3). The only exception is the association of Tlag with the SF-LDQ. However, multiple
regression analysis controlling for use of prokinetic and laxative measures and DID score or
age did not indicate any significant associations between Tlag and the SF-LDQ or any other of
the above-mentioned objectivemeasures of gastrointestinal transport and subjective reports
(all p>0.05). Moreover, colonic transit was not significantly associated with symptoms mea-
sured by the Rome III criteria (neither in the Spearman correlation analysis, coefficient 0.12,
p = 0.5, nor in the multiple regression analysis controlling for use of prokinetic and laxative
measures and DID score or age).
Table 2. Gastrointestinal and colonic transit.
n Median Lower Quartile Upper Quartile
Gastric emptying lag time, minutes 32 134 109 164
Gastric emptying half time, minutes 32 187 168 220
Gastric emptying coefficient 32 2.9 2.4 3.2
Oro-cecal transit time, hours 32 6.3 5.0 7.9
Colonic transit time, hours 30 60.0 48.0 82.0
doi:10.1371/journal.pone.0163779.t002
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Discussion
The current study is the first comprehensive quantitative assessment of the gastrointestinal
transit in its entire length in Duchennemuscular dystrophy patients. Progressive disease was
associated with swallowing impairment, collection of intestinal air and chronic constipation,
(Fig 4) which so far has not been appropriately appreciated in scientific studies.[17, 18] Impor-
tantly, we found that symptoms of impaired gastrointestinal functionwere not significantly
correlated with objectivemeasures of impaired gastrointestinal transport suggesting that
patients may not perceive potentially dangerous constipation requiring therapeutic measures.
The impaired gastrointestinal functionmay further complicate the care of older DMD patients
who already suffer from progressive impairment due to general loss of muscular strength,
respiratory and cardiac failure.
The gastric emptying measures lag time (Tlag) and half time (T1/2) were considerably
increased compared to the healthy volunteers measured by us using the identical test meal with
13C labeling as well as in all the other assessed literature.[31, 35–38] Also the oro-cecal transit
time (OCTT)was substantially longer than in previously published data of healthy subjects.
[25] There was no significant difference between spontaneously breathing patients and patients
on PPV for any of the objectivemeasures of gastrointestinal transit. Our findings also show
Fig 3. Oro-cecal transit assessed by exhaled breath analysis in 33 patients. The median (IQR) changes over baseline of
isotopic enrichment in exhaled breath generated by the 13C enriched test meal are shown. Median oro-cecal transit time was
similar in spontaneously breathing (370 minutes; no positive pressure ventilation; no PPV)) and mechanically ventilated (378
minutes; with positive pressure ventilation; with PPV) patients and considerably longer than in healthy controls (solid vertical line
at 295 minutes).[25]
doi:10.1371/journal.pone.0163779.g003
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Fig 4. Representative radiograph of the abdomen. This is a representative radiograph of a not acutely ill, 38 year old patient with Duchenne
muscular dystrophy. Radiopaque markers and extensive meteorism are seen in the colon. Rods and screws (one of them displaced) for spinal
stabilization and a PEG tube are visible.
doi:10.1371/journal.pone.0163779.g004
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that oro-cecal transit time (OCTT) in Duchenne patients actually is delayed in contrast to ear-
lier studies where large quantities of unmarked lactulose (Duphalac1) in water were used to
assess oro-cecal transit time.[12]We additionally showed that colonic transit time (CTT) was
prolonged, despite extensive use of laxative measures.[33] In 47% of the patients, the colonic
distribution of the radiopaque markers was retained in the rectosigmoid, which indicated pel-
vic outlet obstruction as an additional problem. These findings confirm and extend earlier
studies of colonic transit in children with DMD.[8] Only 12 of our participants did not use lax-
atives, prokinetic medication or enemas and 9 out of 33 had percutaneous enteral nutrition.
Such differences in patient care may have confounded of the current findings to some degree
with a potential underestimation of the impaired gastro-intestinal transport that could not be
completely accounted for by multiple regression analysis.
We speculate as a possible mechanism of the current findings that, in addition to decreased
capabilities of voluntary straining, reducedmyoelectrical slow wave activity along with a
reduced availability of intestinal NO as shown in mice models might be responsible for the
measured increase in gastrointestinal transit time.[13–16] The ampullary predilection of the
colonic marker distributionmight be due to the inability of raising intra-abdominal pressure
and inadequate assumption of an appropriate posture to straighten the anorectal angle.[39]
Within our study population there was a significant inverse correlation between gastric
emptying Tlag as well as T1/2 and older age in the unadjusted model as well as after adjustment
for positive pressure ventilation and use of prokinetic and laxative medication. This might be
explained by a more regular and intensified use of the prokinetic and laxative medication and
possibly to more regular food and fluid intake in assisted living of the participants with more
progressive disease stages. Despite correction in the multivariate model for positive pressure
ventilation a slight decrease of the prolonged gastric emptying Tlag, T1/2 and OCTT could also
be due to a conceivable, albeit unproven side effect of increased ventilation time in patients
with progressive disease. However, higher DID scores were also associated with higher GCSI
scores in the multivariate model including prokinetic and laxative medication use and positive
pressure ventilation. Increased GCSI symptom scores were particularly associated with higher
DID scores in the analysis restricted to ventilated patients only.
As we have previously shown,[7] there is a relevant risk for Duchenne patients to develop
life-threatening constipation in combination with metabolic acidosis when progressive difficul-
ties swallowing lead to insufficient fluid and caloric intake and with further impairment of
Table 3. Spearman correlation analysis.
Age DID GCSI SF-LDQ
Coefficient p Coefficient p Coefficient p Coefficient p
Oro-cecal transit time (OCTT), hours -0.25 0.175 -0.22 0.219 -0.15 0.406 0.10 0.576
Gastric emptying coefficient 0.19 0.299 0.35 0.051 0.16 0.384 0.07 0.697
Gastric emptying half time (T1/2), minutes -0.33 0.064 -0.34 0.059 -0.30 0.090 -0.31 0.087
Gastric emptying lag time (Tlag), minutes -0.36 0.043 * -0.29 0.110 -0.29 0.110 -0.35 0.047*
Colonic transit time (CTT), hours 0.10 0.584 0.06 0.763 n.a. n.a.
Prokinetic / laxative medication 0.40 0.020* 0.40 0.019 * n.a. n.a.
Rome III Criteria 0.37 0.033 * 0.38 0.029 * n.a. n.a.
Gastroparesis Cardinal Symptom Index (GCSI) 0.48 0.004 * 0.44 0.010 * n.a. n.a.
Short-Form Leeds Dyspepsia Question-naire (SF-LDQ) 0.34 0.049 * -0.05 0.778 n.a. n.a.
Age (binary21 years old and > 21 years old). DID: Duchenne muscular dystrophy Impairment and Dependency on care score. GCSI: Gastroparesis
Cardinal Symptom Index. SF-LDQ: Short-Form Leeds Dyspepsia Questionnaire * indicates significant p-values <0.05. n.a.: not applicable.
doi:10.1371/journal.pone.0163779.t003
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gastrointestinal motility. Therefore, it was not an option to stop the patient’s regular medication
in the current study. Also there is no existing control group of ventilated, immobile and age-
matched male patients that don’t suffer frommuscular dystrophy. Potential limitations in our
study were the difficulties the patients had in chewing and swallowing of the test meal in a
timely fashion. Nevertheless, we could show a significant prolongation in T1/2, OCTT, as well as
in CTT in patients with Duchennemuscular dystrophy compared to literature derived normal
data. The results might be evenmore impressive without laxative treatment in any of these
patients. This is clinically particularly relevant because our results suggest that symptoms cannot
predict a possibly dangerous constipation. The lack of significant correlations among symptoms
and objectivemeasures of impaired gastro-intestinal transport may possibly be related to sen-
sory impairment due to expression of dystrophin isoformDP116 in peripheral nerve tissue,[40]
and autosomal homologues of DP116 in sensory ganglia.[41]Moreover, gastro-intestinal symp-
toms may be underreportedby some DMD patients suffering from a variety of severe symp-
toms, including immobility and inadequate respiration, whichmay bemore distressing.
In summary, our findings provide for the first time a comprehensive, quantitative assessment
of the gastrointestinal transport in DMD patients of a broad age range using both objectivemea-
surements and reported symptoms. While earlier studies focusedon specific aspects of intestinal
motility such as gastric emptying[9, 10, 12] or colonic transit in small groups of children with
DMD, the current investigation extends these observations to juvenile and adult DMD patients.
These novel data showing impaired gastrointestinal function but a lack of association between
symptoms and objective assessments are clinically important because they may help to improve
the care of DMD patients by highlighting the impaired gastrointestinal transit as a therapeutic
target that has the potential to prevent life threatening complications.[7] These aspects become
evenmore important with the increasing life expectancyof DMD patients.
Supporting Information
S1 Table. Results by study subject.Data used for analysis sorted by study subject number.
DID score: Duchennemuscular dystrophy Impairment and Dependencyon care score; PEG:
Percutaneous endoscopic gastrostomy use for feeding; tlag: Gastric emptying lag time in min-
utes; thalf: Gastric emptying half time in minutes; gec: Gastric emptying coefficient;OCTT:
Oro-cecal transit time, hours; CTTColonic transit time, hours; Ventilation: Ventilatory sup-
port is coded as follows 0 = no ventilation, 1 = ventilatory support during night time only (non
invasive), 2 = ventilatory support during 24 hours a day (non invasive), 3 = permanent ventila-
tory support by means of tracheostomy; constipation = Binary result for constipation based on
the Rome III criteria for constipation and the absence for criteria of irritable bowel syndrome;
SF-LDQ: Short-Form Leeds DyspepsiaQuestionnaire; GCSI: Gastroparesis Cardinal Symptom
Index
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